.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
Baxter
Dow
QuintilesIMS
US Department of Justice
Medtronic
Daiichi Sankyo
Mallinckrodt
Teva

Generated: November 25, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202333

« Back to Dashboard
NDA 202333 describes SODIUM POLYSTYRENE SULFONATE, which is a drug marketed by Citrusphrma, Cmp Pharma Inc, Eci Pharms Llc, Ailex Pharms Llc, Morton Grove, Belcher Pharms Llc, Epic Pharma Llc, West-ward Pharms Int, Roxane, Nuvo Pharm Inc, Wockhardt, and Paddock Llc, and is included in twelve NDAs. It is available from eleven suppliers. Additional details are available on the SODIUM POLYSTYRENE SULFONATE profile page.

The generic ingredient in SODIUM POLYSTYRENE SULFONATE is sodium polystyrene sulfonate. There are one thousand four hundred drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the sodium polystyrene sulfonate profile page.

Summary for 202333

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 202333

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SODIUM POLYSTYRENE SULFONATE
sodium polystyrene sulfonate
POWDER;ORAL, RECTAL 202333 ANDA PuraCap Laboratories, LLC 24658-760 24658-760-16 453.6 g in 1 JAR (24658-760-16)
SODIUM POLYSTYRENE SULFONATE
sodium polystyrene sulfonate
POWDER;ORAL, RECTAL 202333 ANDA Epic Pharma, LLC 42806-013 42806-013-96 453.6 g in 1 JAR (42806-013-96)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORAL, RECTALStrength453.6GM/BOT
Approval Date:Mar 19, 2014TE:AARLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Harvard Business School
Colorcon
Accenture
Argus Health
Merck
Deloitte
Moodys
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot